Journal List > Immune Netw > v.5(2) > 1033698

TOOLS
Jun, Jaffee, and Kim: Application of Apoptogenic Pretreatment to Enhance Anti-tumor Immunity of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)-secreting CT26 Tumor Cells
Original Article

Immune Network 2005; 5(2): 110-116.

Published online: 30 June 2005

DOI: https://doi.org/10.4110/in.2005.5.2.110

Application of Apoptogenic Pretreatment to Enhance Anti-tumor Immunity of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)-secreting CT26 Tumor Cells

Do Youn Jun1, Elizabeth M Jaffee2, Young Ho Kim3

1Institute of Genetic Engineering, Kyungpook National University, Daegu, Korea.

2Division of Immunology and Hematopoiesis, The Sidney Kimmel Comprehensive Center at Johns Hopkins, Baltimore, Maryland, USA.

3Laboratory of Immunobiology, Department of Microbiology, College of Natural Sciences, Kyungpook National University, Daegu, Korea.

Correspondence to: Young Ho Kim, Laboratory of Immunobiology, Department of Microbiology, College of Natural Sciences, Kyungpook National University, 1370 Sankyuk-dong, Buk-gu, Daegu 702-701, Korea. (Tel) +82-53-950-5378, (Fax) +82-53-955-5522, ykim@knu.ac.kr

Copyright © 2005 The Korean Association of Immunologists

(open-access):

This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

As an attempt to develop a strategy to improve the protective immune response to GM-CSF-secreting CT26 (GM-CSF/CT26) tumor vaccine, we have investigated whether the apoptogenic treatment of GM-CSF/CT26 prior to vaccination enhances the induction of anti-tumor immune response in mouse model.

Methods

A carcinogen-induced mouse colorectal tumor, CT26 was transfected with GM-CSF gene using a retroviral vector to generate GM-CSF-secreting CT26 (CT26/GM-CSF). The CT26/GM-CSF was treated with γ-irradiation or mitomycin C to induce apoptosis and vaccinated into BALB/c mice. After 7 days, the mice were injected with a lethal dose of challenge live CT26 cells to examine the protective effect of tumor vaccination in vivo.

Results

Although both apoptotic and necrotic CT26/GM-CSF vaccines were able to enhance anti-tumor immune response, apoptotic CT26/GM-CSF induced by pretreatment with γ-irradiation (50,000 rads) was the most potent in generating the anti-tumor immunity, and thus 100% of mice vaccinated with the apoptotic cells remained tumor free for more than 60 days after tumor challenge.

Conclusion

Apoptogenic pretreatment of GM-CSF-secreting CT26 tumor vaccine by γ-irradiation (50,000 rads) resulted in a significant enhancement in inducing the protective anti-tumor immunity. A rapid induction of apoptosis of CT26/GM-CSF tumor vaccine at the vaccine site might be critical for the enhancement in anti-tumor immune response to tumor vaccine.

Keywords: CT26 tumor, GM-CSF, apoptotic pretreatment, cancer vaccine, anti-tumor immune response

TOOLS
Similar articles